Leiden, The Netherlands – 11 December 2025 – ProteoNic BV, a leading provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic® technology has been licensed by Ginkgo Bioworks (NYSE: DNA) for use in a project awarded to Ginkgo by the Biomedical Advanced Research and Development Authority (BARDA). The project, funded through BARDA’s Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), aims to develop innovatio ...